The therapeutic community is excited with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s demonstrating significant efficacy in clinical trials for addressing obesity. Unlike some available weight loss treatments, retatrutide appears to offer a significant substantial decrease in body mass and benefit metabolic heal